ReviewCurrent issues in molecular biology2026
Metformin, SGLT2 Inhibitors, and Intermittent Fasting: Convergent Pathways to Healthspan Extension, Cardiovascular Longevity, and Cancer Prevention-A Narrative Review.
Review in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The biology of aging and the epidemiology of cardiovascular disease share a common molecular pathway expressed through nutrient-sensing kinases, mitochondrial redox state, and chronic inflammation. Three interventions have independently emerged as translators of that interconnection into clinical benefit: metformin, a biguanide that has evolved from a first-line anti-diabetic into the world's most extensively studied putative geroprotector; the sodium-glucose cotransporter-2 inhibitors (SGLT2is), pharmacological generators of a fasting-mimetic state that has reshaped heart failure outcomes across the ejection-fraction spectrum; and intermittent fasting (IF), the evolutionary archetype from which both agents partially derive their effects on longevity. Based on the synthetized evidence, we propose a stage-stratified clinical framework for integrated deployment. To find the manuscripts relevant for our narrative review, we searched the medical literature by using key words ("metformin"; "SGLT2i"; "intermittent fasting"; "health span"; "cardiovascular longevity"; "cancer chemoprevention"; "gut microbiome"; "geroprotection"; "heart failure") combined through Boolean operators (AND/OR). This narrative review integrates preclinical mechanistic evidence, landmark randomized controlled trial data, and emerging data on cancer chemoprevention and gut microbiome remodeling to provide a rigorous, side-by-side analysis of all three strategies. We delineate molecular convergence on adenosine monophosphate kinase (AMPK) activation, mechanistic target of rapamycin complex 1 (mTORC1) suppression, enhanced autophagy, mitochondrial renewal, inflammatory responses, and anti-cancer biology, while mapping critical divergences in specific populations, lifespan timing, combinability, and safety. Our proposed framework has to be treated with caution, as it is based on the current evidence base, which lacks dedicated outcome trials for IF and published randomized clinical trial data for metformin in non-diabetic adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.